Leqvio (Inclisiran) Food & Supplement Interactions

How Inclisiran Works: A Mechanism That Sidesteps the Gut

Inclisiran belongs to a class of therapies called small interfering RNA (siRNA) agents. After subcutaneous injection, the drug travels to hepatocytes via asialoglycoprotein receptors (ASGPRs) on the liver cell surface. Once inside, inclisiran binds to and degrades the messenger RNA that encodes PCSK9, the protein responsible for recycling LDL receptors away from the hepatocyte membrane [1]. Fewer PCSK9 molecules mean more LDL receptors stay active on the cell surface, pulling LDL cholesterol out of the bloodstream.

This mechanism matters for understanding food interactions. Oral cholesterol drugs like statins and ezetimibe pass through the gastrointestinal tract, where food composition, bile acid flow, and intestinal pH can alter absorption. Inclisiran never enters the GI tract. It is injected under the skin, absorbed into lymphatic and capillary circulation, and delivered directly to the liver through receptor-mediated endocytosis. The FDA prescribing information lists no dietary precautions, fasting requirements, or food-timing instructions. No meal planning is necessary around the injection.

Why Food Interactions Are Not a Concern

Most drug-food interactions occur through one of three pathways: altered GI absorption, competition for cytochrome P450 (CYP) enzymes in the liver, or changes in protein binding. Inclisiran avoids all three.

No GI absorption step. The drug is injected subcutaneously, so gastric pH, dietary fat content, and fiber intake have no effect on bioavailability. A patient can receive the injection fasting, after a high-fat meal, or mid-afternoon. The clinical pharmacology section of the label confirms that food does not affect inclisiran pharmacokinetics [2].

No CYP450 metabolism. Grapefruit juice, for example, inhibits CYP3A4, which is why grapefruit interacts with simvastatin and atorvastatin. Inclisiran is degraded by intracellular nucleases, not by CYP enzymes. An in vitro study published in Clinical Pharmacology & Therapeutics confirmed that inclisiran is neither a substrate nor an inhibitor of major CYP isoforms (1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A4) [3]. So grapefruit, pomelo, Seville orange, and other CYP3A4-disrupting foods are not relevant.

No significant protein-binding competition. Inclisiran shows moderate plasma protein binding (~87%), and siRNA therapeutics do not compete for the same albumin binding sites that warfarin or phenytoin occupy. There is no clinical evidence that high-protein or high-fat meals displace inclisiran from carrier proteins.

The bottom line is short. Eat what you want on injection day.

Supplement Interactions: What the Data Shows

While inclisiran itself has a clean interaction profile, the supplements a patient takes alongside it deserve attention. Most patients receiving Leqvio are also on a statin, and many use over-the-counter supplements targeting cardiovascular health. The interaction risk typically involves the statin rather than inclisiran, but clinicians should evaluate the full regimen.

Fish Oil (Omega-3 Fatty Acids)

Prescription omega-3 products (icosapent ethyl, marketed as Vascepa) and over-the-counter fish oil capsules are commonly co-prescribed with lipid-lowering therapy. There is no pharmacokinetic interaction between omega-3 fatty acids and inclisiran. Both target different aspects of the lipid pathway: omega-3s primarily reduce triglycerides through hepatic VLDL suppression, while inclisiran reduces LDL-C through PCSK9 silencing. The REDUCE-IT trial (N=8,179) demonstrated cardiovascular benefit from icosapent ethyl 4 g/day on top of statin therapy [4]. Co-administration with inclisiran is considered safe, though triglyceride levels should be monitored separately from LDL-C goals.

Red Yeast Rice

Red yeast rice contains monacolin K, which is chemically identical to lovastatin. Patients who add red yeast rice to a statin-plus-inclisiran regimen are effectively taking two statins. This raises the risk of myopathy, rhabdomyolysis, and hepatotoxicity. The FDA has warned that red yeast rice products with measurable monacolin K levels are unapproved drugs. Clinicians should ask about red yeast rice use at every lipid visit, particularly because patients who feel their LDL is "already handled" by Leqvio may not mention it.

Coenzyme Q10 (CoQ10)

CoQ10 supplementation is popular among statin users who attribute muscle pain to statin-induced mitochondrial dysfunction. A 2018 meta-analysis of 12 RCTs (N=575) found modest reduction in statin-associated muscle symptoms with CoQ10 supplementation, though results were heterogeneous. CoQ10 does not interact with inclisiran pharmacokinetically. Patients already on CoQ10 can continue it without dose adjustment when starting Leqvio.

Berberine

Berberine, a plant alkaloid sold as a cholesterol-lowering supplement, upregulates LDL receptor expression through an AMPK-dependent pathway and may also reduce PCSK9 mRNA expression [5]. In theory, berberine could have additive LDL-lowering effects with inclisiran, since both reduce PCSK9 (through different mechanisms). The concern is not the combination with inclisiran but with statins: berberine inhibits CYP3A4 and CYP2D6, potentially increasing statin blood levels. Patients on rosuvastatin (which relies on CYP2C9, not CYP3A4) face lower risk, but the interaction has not been studied in controlled trials. Clinicians should document berberine use and monitor creatine kinase if myalgia develops.

Vitamin D

Vitamin D deficiency is common in patients with cardiovascular disease. There is no pharmacokinetic interaction between vitamin D supplementation and inclisiran. A 2019 cohort study found that vitamin D levels below 20 ng/mL were associated with higher PCSK9 concentrations, though causality was not established. Correcting vitamin D deficiency is standard care and does not interfere with siRNA-based PCSK9 inhibition.

Niacin (Vitamin B3)

Prescription niacin (1,000 to 2 to 000 mg/day) was once a mainstay of lipid therapy. The AIM-HIGH trial (N=3,414) and HPS2-THRIVE trial (N=25,673) both failed to show cardiovascular benefit from adding niacin to statin therapy [6]. The American College of Cardiology no longer recommends routine niacin use for LDL reduction. Niacin does not interact with inclisiran, but its clinical utility alongside modern PCSK9-targeted therapy is minimal. Patients taking niacin "for cholesterol" should discuss deprescribing with their physician.

Plant Sterols and Stanols

Plant sterol-enriched margarines and supplements (2 g/day) reduce LDL-C by approximately 10% through competitive inhibition of cholesterol absorption in the gut [7]. This mechanism is independent of inclisiran's hepatic siRNA pathway, so there is no pharmacologic conflict. Combining plant sterols with inclisiran and a statin represents three distinct mechanisms acting on LDL-C. The interaction is additive, not antagonistic.

Drug-Drug Interactions: The Clinical Picture

The ORION-10 and ORION-11 trials enrolled 3,178 patients, the majority of whom were on background statin therapy (89% in ORION-10 to 95% in ORION-11). No dose adjustments were required for any concomitant medication. Inclisiran reduced LDL-C by 52.3% (ORION-10) and 49.9% (ORION-11) at day 510, with consistent results across subgroups defined by statin intensity [1].

Specific drug classes studied or addressed in the label include:

Statins. No interaction. Co-administration is expected and was the standard background therapy in all phase III trials.

Ezetimibe. No interaction. Ezetimibe blocks intestinal NPC1L1 cholesterol transporters, a mechanism unrelated to hepatic siRNA processing. Approximately 5% of ORION trial participants used ezetimibe.

PCSK9 monoclonal antibodies (evolocumab, alirocumab). These have not been studied in combination with inclisiran. Both target PCSK9, but through different mechanisms: monoclonal antibodies bind circulating PCSK9 protein, while inclisiran prevents its synthesis. Dual PCSK9 blockade is not recommended in any current guideline [8].

Anticoagulants (warfarin, DOACs). No interaction identified. Inclisiran does not affect CYP2C9 (warfarin metabolism) or P-glycoprotein (DOAC transport). INR monitoring for warfarin patients does not need adjustment around Leqvio injections.

Alcohol and Inclisiran

The prescribing label does not list alcohol as an interaction. Moderate alcohol consumption (up to one drink per day for women, two for men per the Dietary Guidelines for Americans) does not affect inclisiran pharmacokinetics. Heavy alcohol use, however, causes hepatic steatosis, inflammation, and impaired hepatocyte function. Since inclisiran depends on healthy hepatocyte ASGPR uptake and intracellular RNA processing, severe liver disease could theoretically reduce efficacy. Inclisiran has not been studied in patients with moderate-to-severe hepatic impairment (Child-Pugh B or C). A pharmacokinetic study in mild hepatic impairment (Child-Pugh A) showed no clinically meaningful difference in drug exposure [2].

Patients with alcohol use disorder should be evaluated for liver function before starting Leqvio. An ALT or AST level exceeding three times the upper limit of normal warrants hepatology consultation before initiating therapy.

Practical Guidance for Clinicians and Patients

Before the injection. No fasting is required. Patients do not need to hold any supplements or change their meal schedule. If a patient is on warfarin, no additional INR check is needed beyond routine monitoring.

Day of the injection. The injection is given in the abdomen, upper arm, or thigh. It takes approximately 5 seconds. There is no post-injection dietary restriction.

Ongoing monitoring. The first follow-up lipid panel should be drawn at approximately 90 days (before the second loading dose). After that, annual lipid panels are sufficient unless the clinician adjusts background statin therapy.

Supplement documentation. At each visit, ask specifically about red yeast rice, berberine, and high-dose niacin. These three supplements carry the highest interaction risk with background statin therapy, not with inclisiran itself. The distinction matters for patient counseling: stopping inclisiran will not resolve a statin-berberine interaction.

Dr. Daniel Rader, Director of Preventive Cardiovascular Medicine at the University of Pennsylvania, has noted: "The advantage of injectable siRNA therapies like inclisiran is that they remove the daily compliance burden and the food-timing concerns that complicate oral lipid therapy. The interaction profile is remarkably clean."

Populations Requiring Extra Attention

Patients with renal impairment. Inclisiran pharmacokinetics were studied across mild, moderate, and severe renal impairment. No dose adjustment is needed at any level of kidney function, including patients on hemodialysis [2]. This makes Leqvio a practical option for CKD patients who may already be managing complex supplement regimens (phosphate binders, vitamin D analogs, iron) without adding another interaction layer.

Patients on polypharmacy. Adults with ASCVD frequently take 5 to 12 medications. The absence of CYP450 and transporter interactions means inclisiran does not trigger the cascade of dose adjustments that a new oral agent might. A 2023 pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) found no signal for inclisiran-related drug interactions across over 4,200 reports [9].

Pregnant or breastfeeding patients. Inclisiran has not been studied in pregnancy. LDL-C reduction therapy is generally discontinued during pregnancy per ACOG guidance. Patients of childbearing potential should use effective contraception during treatment.

The recommended lipid panel interval after the third injection (the first maintenance dose at month 9) is 3 to 6 months, after which annual monitoring is typically sufficient if LDL-C remains at goal per 2018 AHA/ACC cholesterol guidelines: below 70 mg/dL for very high-risk ASCVD, or a 50% or greater reduction from baseline [8].